Fanzors are RNA-Guided Nucleases Encoded in Eukaryotic Genomes
This invention introduces compositions and methods for targeting polynucleotides with eukaryotic RNA-guided nucleases, particularly Fanzors which are programmable RNA-guided DNA endonucleases, useful for genome editing in human cells and other organisms. Compositions include Fanzor polypeptides with RuvC domains and fRNA molecules directing them to target specific sequences. This technology enables precise targeting of specific polynucleotide sequences, highlighting the biotechnological potential of eukaryotic RNA-guided nucleases and potentially revolutionizing gene editing and therapeutic applications.
Researchers
-
fanzors are rna-guided nucleases encoded in eukaryotic genomes
United States of America | Pending -
fanzors are rna-guided nucleases encoded in eukaryotic genomes
Patent Cooperation Treaty | Pending
Technology
The Fanzor polypeptide consists of two main parts: a RuvC domain and an fRNA molecule. The fRNA molecule acts as a guide, directing the Fanzor polypeptide to a specific target sequence in the genetic material. The RuvC domain within the Fanzor polypeptide plays a crucial role to cleave/modify the target sequence. As a whole, the Fanzor protein acts as an enzyme to allow precise manipulation of genetic material.
Problem Addressed
Challenges in gene editing lie in accurately editing specific DNA or RNA sequences without affecting other parts of the genome. Furthermore, existing technologies tend to lack precision or efficiency, creating a need for safe and effective gene editing tools for research and medicine. Fanzors address these problems by using RNA-guided endonucleases to precisely target specific genetic sequences. This innovation has the potential to revolutionize gene editing and therapeutic applications while minimizing risks associated with unintended mutations.
Advantages
- Precise targeting of DNA or RNA sequences
- Improved safety and efficiency compared to existing methods
- Versatility for various research, clinical, and therapeutic applications
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.